Zimmer Biomet's new CEO is focused on restoring inventory, physician relationships, and trust.
Wide-moat Zimmer Biomet has, again, run into a speedbump with another Form 483 letter from the Food and Drug Administration. After looking over the specific observations that need to be addressed, we’re leaving our fair value estimate unchanged at $130 per share. Unlike the earlier Form 483 from the fall of 2016, the most recent one highlights issues with a legacy Zimmer manufacturing facility. We think the nature of these latest observations will be more easily and quickly addressed compared wi...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.